Research programme: LDL receptor-transferrin fusion protein - Shire Pharmaceuticals

Drug Profile

Research programme: LDL receptor-transferrin fusion protein - Shire Pharmaceuticals

Alternative Names: LDL receptor-transferrin fusion protein research programme - Transkaryotic Therapies; LDL receptor-transferrin fusion protein research programme: Shire Pharmaceuticals; LDL-cholesterol lowering therapies research programme - Transkaryotic Therapies; LDLR/TF; Research programme: LDL-cholesterol lowering therapies - Shire Pharmaceuticals; TX-1501

Latest Information Update: 19 Mar 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Shire Pharmaceuticals Group
  • Class Recombinant fusion proteins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hyperlipoproteinaemia type II

Most Recent Events

  • 28 Jul 2005 Transkaryotic Therapies has been acquired and merged into Shire Pharmaceuticals Group
  • 16 Feb 2005 Preclinical trials in Familial hypercholesterolaemia in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top